BeOne Medicines Ltd. 4

CEO John Oyler sold 240,743 American Depositary Shares of BeOne Medicines Ltd. (ONC) in open-market transactions over August 10–12, 2026, liquidating his directly held ADS position.

On August 10–12, 2026, John Oyler, Chief Executive Officer of BeOne Medicines Ltd., executed a series of open‑market sales of American Depositary Shares (each representing 13 ordinary shares) under a pre-arranged Rule 10b5‑1 trading plan. Across numerous tranches at weighted average prices between roughly $350 and $367 per ADS, he reduced his directly held ADS position from 240,743 to zero, realizing an estimated $13 million in gross proceeds. The Form 4 also notes substantial indirect holdings of ordinary shares held through various trusts and an LLC, many of which he disclaims beneficial ownership, as well as a Roth IRA account; the reported ADS sales affect only the directly held ADS balance and do not eliminate his broader economic exposure to the company.

Filing Facts

CIK

1651308

Ticker

ONC

Form

4

Source Type

fda

Accession

0001042047-26-000019

Alert Tier

7